SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Piramal Pharma Ltd (PPLPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543635 NSE: PPLPHARMA Pharmaceuticals & Drugs | Small Cap | Piramal Pharma Share Price

₹167.15 -1.70 (-1.01%)

As on 10-Jun'26 12:28

Piramal Pharma Ltd (PPLPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543635 NSE: PPLPHARMA Pharmaceuticals & Drugs | Small Cap | Piramal Pharma Share Price

₹167.15 -1.70 (-1.01%)

As on 10-Jun'26 12:28

Key Metrics
Valuation Multiples
Market Cap
₹22,480 Cr.
Current Price
₹167.2
52-Week Low / High
₹133 / 221
TTM EPS
₹5.3
TTM Sales
₹4,782 Cr.
Book Value per Share
₹61.2
P/E Ratio
32.11
Lower than its 5-year historical median
Industry PE
47
Price to Book (P/B)
2.76
Lower than its 5-year historical median
Price to Sales (P/S)
4.70
In line with its 5-year historical median
EV/EBITDA
17.33
Lower than its 5-year historical median
Dividend Yield
0.06%
Profitability Efficiency
Return on Equity (ROE)
9.83%
Outperforms industry median
Return on Capital Employed (ROCE)
12.40%
Outperforms industry median
Return on Assets (ROA)
6.64%
Operating Profit Margin
19.2%
Net Profit Margin
13.08%
Gross Profit Margin
20.8%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
20.4%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
68.36%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
76.73%
Asset Quality
Promoter Holding
34.86%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹6,814 Cr.
Equity
₹1,331.4 Cr.
Face Value
₹10
All Time Low / High
₹61.65 / 307.85

Piramal Pharma stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Piramal Pharma Ltd a good quality company?
Piramal Pharma Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Piramal Pharma Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Piramal Pharma Ltd vs industry peers?
Piramal Pharma Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Piramal Pharma Ltd?
Promoters hold 34.86% of the Piramal Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Piramal Pharma Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 33.37% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Piramal Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ16.2%9.9%3.6%8.3%12.4%-
Value Creation
Index ⓘ		0.4-0.1-0.7-0.40.1-

Growth Parameters ⓘ
Sales ⓘ2,9393,3403,4434,3905,2864,782
Sales YoY Gr.-13.7%3.1%27.5%20.4%-
Adj EPS ⓘ5.22.9-0.22.85.25.3
YoY Gr.--45.1%-106.6%NA88.1%-
BVPS (₹) ⓘ40.342.243.150.555.861.2
Adj Net
Profit ⓘ		533349-23.7367693700
Cash Flow from Ops. ⓘ34.724971.5358549-
Debt/CF from Ops. ⓘ4.84.622.83.22.2-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA16.5%20.4%
Adj EPS ⓘNANA22.1%88.1%
BVPSⓘNANA9.8%10.4%
Share Price - - 24.9% -18.9%

Key Financial Parameters ⓘ

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		137.6-0.56.19.89
Op. Profit
Mgn % ⓘ		21.114.32.813.719.213.4
Net Profit
Mgn % ⓘ		18.110.5-0.78.413.114.6
Debt to
Equity ⓘ		00.20.30.20.20.1
Working Cap
Days ⓘ		0287329327310141
Cash Conv.
Cycle ⓘ		06784727555

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales2,9393,3403,4434,3905,286
Operating Expenses ⓘ + 2,3202,8653,3463,7914,277
Manufacturing Costs315367426431489
Material Costs1,2281,5621,7682,1092,246
Employee Cost 395448549614736
Other Costs ⓘ 382488602637806
Operating Profit ⓘ 619475985991,009
Operating Profit Margin (%) 21.1%14.2%2.8%13.7%19.1%
Other Income ⓘ + 198225341221239
Exceptional Items ⓘ 18-15-700
Interest ⓘ 557116107115
Depreciation ⓘ 144165192205222
Profit Before Tax ⓘ 687462124508911
Tax ⓘ 1159554116220
Profit After Tax 57236870391691
PAT Margin (%) 19.5%11.0%2.0%8.9%13.1%
Adjusted EPS (₹)5.63.00.63.05.2
Dividend Payout Ratio (%)0%0%0%3.70%2.70%

Valuation of Piramal Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 4,1015,1235,2626,6857,389
Share Capital ⓘ 9951,1861,1931,3231,324
Reserves ⓘ 3,1063,9374,0685,3626,065
Debt +1658671,3138961,009
Long Term Debt0477592364357
Short Term Debt165390720532652
Minority Interest00000
Trade Payables5846477621,1081,185
Others Liabilities ⓘ 1,0029429601,1911,376
Total Liabilities ⓘ 5,8527,5798,2969,87910,958

Fixed Assets

Net Fixed Assets ⓘ +1,6272,4392,6022,6122,894
Gross Block2,2603,2253,5653,7674,258
Accumulated Depreciation6337869631,1551,364
CWIP ⓘ 121405417533327
Investments ⓘ 1,5921,6301,7471,7083,105
Inventories4215368191,1531,205
Trade Receivables8409899101,3311,667
Cash Equivalents 15213764242178
Others Assets ⓘ 1,1001,4441,7382,3001,582
Total Assets ⓘ 5,8527,5798,2969,87910,958

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 3524972358549
PBT ⓘ 669477124508911
Adjustment ⓘ -3104351221265
Changes in Working Capital ⓘ -228-168-43-293-393
Tax Paid ⓘ -95-103-60-78-234
Cash Flow From Investing Activity ⓘ + -4,383-1,246-435-636-550
Capex -55-231-243-325-282
Net Investments -3,710-137-824061
Others ⓘ -618-877-110-350-329
Cash Flow From Financing Activity ⓘ + 4,494896290451-62
Net Proceeds from Shares ⓘ 3,448001,0503
Net Proceeds from Borrowing ⓘ 0697134-287-33
Interest Paid ⓘ -4-45-101-101-127
Dividend Paid ⓘ 0-50-670-14
Others ⓘ 1,050294324-211110
Net Cash Flow ⓘ 146-100-73174-63

Financial Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)13.947.971.346.559.83
ROCE (%)16.219.863.648.3312.4
Asset Turnover Ratio0.520.510.450.510.52
PAT to CFO Conversion(x)0.060.681.030.920.79
Working Capital Days
Receivable Days100.4098.409788.90100.50
Inventory Days50.3051.5069.2078.2079.10
Payable Days173.70143.90145.40161.80186.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Piramal Pharma Ltd FAQs

The current trading price of Piramal Pharma on 10-Jun-2026 12:28 is ₹167.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2026 the market cap of Piramal Pharma stood at ₹22,479.8 Cr

The latest P/E ratio of Piramal Pharma as of 09-Jun-2026 is 32.11.

The latest P/B ratio of Piramal Pharma as of 09-Jun-2026 is 2.76.

The 52-week high of Piramal Pharma is ₹220.9 and the 52-week low is ₹132.5.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Piramal Pharma is ₹4,782 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Piramal Pharma Ltd is a below average quality company.

The key valuation ratios of Piramal Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Piramal Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Piramal Pharma Ltd

Piramal Pharma (PPL) is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operates under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (PCH) business, selling well-known OTC brands. 

Business area of the company

The company is one of the India’s largest Pharmaceutical Company. PPL offers a portfolio of differentiated products and services through its global development and manufacturing facilities and a global distribution network in various countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the- counter products. 

Businesses of the company

Piramal Pharma Solutions: Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. PPS serves customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables PPS to offer a comprehensive range of services, including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.

Piramal Critical Care: Piramal Critical Care (PCC), a business division of Piramal Pharma, is one of the leaders in inhaled anesthetics and a global player in hospital generics. PCC is motivated by its vision of commitment to delivering critical care solutions for patients and healthcare providers across the globe, while achieving sustainable and profitable growth for all the stakeholders.

Piramal Consumer Healthcare: Piramal Consumer Healthcare (PCH) is one of the fastest-growing businesses of Piramal Pharma. It is among the leading players in the Indian self-care space, with established brands like Littles, Lacto Calamine, i-pill, Tetmosol. Polycrol and Tri-Activ, among others, in the Indian Consumer Healthcare market. The PCH portfolio consists of branded consumer healthcare and wellness products, primarily in areas of routine health disruption and proactive care, expanding across key over the counter (OTC) categories such as Analgesics, Gastro-Intestinal, Hygiene, Skincare, Vitamins and Supplements, Women Care, Baby Care and Kids’ wellness.

Awards and recognition

  • 2019: Piramal Pharma honoured with 2019 Global Customer Service Leadership award by Frost & Sullivan.
  • 2020: Piramal Pharma Solution received 'Manufacturing Supply Chain Operational Excellence – Pharmaceuticals' award at 7th and 9th Edition of Manufacturing Supply Chain Awards.
  • 2020: Piramal Pharma Solutions was recognised as the 'Best Contract Manufacturing (CMO) Provider' at the 7th Annual World ADC Awards.
  • 2021: Piramal Pharma Solutions was awarded the ‘2021 Global Contract Development and Manufacturing Organisation Customer Value Leadership Award’ by Frost & Sullivan at the 2021 MEASA Best Practices Awards.
  • 2022: Piramal Pharma Ltd-Consumer Products Division was certified by Great Place to Work® Institute, India.
  • 2022: Piramal Pharma Ltd - Consumer Products Division was awarded Best Sales Automation (in CPG) by Bizom.
  • 2023: Piramal Pharma Solutions retains No. 1 position in Indian Bioservices Industry.
  • 2024: Piramal Pharma Solutions Receives the 2024 CDMO Leadership Award.
  • 2025: Piramal Pharma Solutions Wins Outsourced Pharma's CDMO Leadership 2025 Award.

Milestones

  • 1988: Acquired Nicholas Laboratories, marking entry into pharmaceuticals.
  • 1991: Commissioned first formulation plant in Pithampur, Madhya Pradesh, expanding operations in 1992.
  • 1992: Renamed Nicholas Laboratories Ltd. to Nicholas Piramal India Ltd.
  • 1993: Entered into a joint venture with Allergan, a leader in ophthalmic products.
  • 1993: Acquired Roche India’s domestic formulations and nutrition products/ services business.
  • 1994: Acquired Boehringer Mannheim's formulation plant in Mahad.
  • 1995: Acquired the bulk drug division of Sumitra Pharmaceutical and Chemical Ltd., Hyderabad.
  • 1996: Boehringer Mannheim fully acquired.
  • 2000: Began collaborative research in gene technology with the Centre for Biochemical Technology.
  • 2002: Acquired ICI Pharma.
  • 2003: Acquired Global Bulk Drugs.
  • 2005: Acquired Avecia Pharmaceuticals.
  • 2006: Acquired Morpeth facility from Pfizer.
  • 2009: Greenfield investment in Ahmedabad (PPDS).
  • 2011: Acquired Oxygen Bio Research, a CRO based in Ahmedabad.
  • 2012: Piramal Healthcare renamed to Piramal Enterprises, integrating pharma, Financial Services (FS), and new businesses created / acquired – FS and DRG.
  • 2015: Acquired Kentucky-based CDMO Coldstream Laboratories Inc.
  • 2016: Acquired Ash Stevens Inc., a U.S.-based developer specializing in high-potency APIs.
  • 2020: Acquired solid oral dosage drug product facility in Sellersville, Pennsylvania, from G&W Laboratories Inc.
  • 2020: Becomes a subsidiary of Piramal Enterprises and receives strategic growth investment by Carlyle.
  • 2021: Acquired Hemmo Pharmaceuticals, a leading Indian manufacturer of peptide APIs.
  • 2021 Acquired a minority stake in Yapan Bio, an Indian CDMO specializing in biologics and vaccines.
  • 2022: NCLT approves Piramal Enterprises demerger and Piramal Pharma Limited lists on BSE and NSE.
  • 2022: Opens a new state-of-the-art API manufacturing facility in Aurora, Canada.
  • 2023: Opens a new state-of-the-art API manufacturing facility in Riverview, Michigan.
  • 2023: Opens its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.
  • 2024: PPL forays into men’s grooming market in India with the launch of BOHEM.
  • 2024: Piramal Pharma’s GHG Commitment Validated and Approved by SBTi.
  • 2024: Capacity Expansion at Piramal Pharma Solutions’ Facility at Lexington, Kentucky.
  • 2024: Piramal Pharma ropes in Mrunal Thakur as its brand ambassador for Lacto Calamine.
  • 2025: Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts.
  • 2025: Piramal Critical Care Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP.
  • 2025: Piramal Pharma ropes in Yami Gautam as its brand ambassador for Brand,Little’s.
  • 2025: Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility.
  • 2025: Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities.
  • 2026: Piramal Pharma Limited’s Consumer Healthcare launches Little’s AquaSense Baby Wipes - 99.9% Water.
  • 2026: Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities.
  • 2026: Piramal Consumer Healthcare’s Tetmosol Announces Pankaj Tripathi as Brand Ambassador; Launches New Campaign and Expands Portfolio.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×